UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Income Statement [Abstract]
Revenue, Product and Service [Extensible List]	Service [Member]	Service [Member]
Oncology services revenue	$ 14,061	$ 12,561
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Service [Member]	Service [Member]
Cost of oncology services	$ 7,072	$ 7,684
Research and development	1,454	2,793
Sales and marketing	1,679	1,696
General and administrative	2,527	2,940
Total costs and operating expenses	12,732	15,113
Income (loss) from operations	1,329	(2,552)
Other income	5	14
Income (loss) before provision for income taxes	1,334	(2,538)
Provision for income taxes	21	28
Net income (loss)	$ 1,313	$ (2,566)
Net income (loss) per common share outstanding
Basic (in dollars per share)	$ 0.10	$ (0.19)
Diluted (in dollars per share)	$ 0.09	$ (0.19)
Weighted average common shares outstanding
Basic (in shares)	13,593,766	13,506,782
Diluted (in shares)	14,042,379	13,506,782